High Growth Tech Stocks To Watch In US April 2026

The United States market has remained flat over the past week but has experienced a significant 30% increase over the past year, with earnings projected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue expansion and innovation in a dynamic economic environment.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: One Stop Systems, Inc. specializes in designing, manufacturing, and marketing rugged high-performance computing and storage systems for edge applications in AI, machine learning, sensor processing, and autonomy with a market cap of $257.60 million.

Operations: OSS focuses on the design and manufacture of high-performance computer systems and components, generating $32.22 million in revenue. The company serves edge applications in AI, machine learning, sensor processing, and autonomy across domestic and international markets.

One Stop Systems (OSS) has demonstrated a robust recovery, transitioning from a net loss in 2025 to projecting substantial revenue growth of 20-25% for 2026. This turnaround is underscored by a recent significant order from the renewable energy sector, potentially worth up to $10 million over five years, signaling OSS’s strategic entry into high-demand markets. Additionally, the company’s involvement with the U.S. Navy and defense contractors for the P-8A Poseidon aircraft highlights its critical role in advanced data storage solutions for military applications. These developments not only reflect OSS’s capacity to secure and expand influential commercial relationships but also its potential resilience in navigating tech industry challenges.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CareDx, Inc. focuses on delivering solutions to enhance transplant patient outcomes and promote organ health globally, with a market capitalization of approximately $1.06 billion.

Operations: The company generates revenue primarily through its biotechnology segment, totaling $379.81 million.

CareDx, with its recent introduction of AlloSeq Nano and VANTx platform, underscores a strategic push into advanced transplant diagnostics and data analytics. The company’s R&D dedication is evident as it channels significant resources into innovation—evidenced by a robust pipeline of products designed to enhance the precision and speed of transplant diagnostics. This focus on high-resolution genotyping technologies and AI-powered platforms not only enhances CareDx’s competitive edge but also meets critical healthcare needs more efficiently. With an expected revenue range for 2026 between $420 million to $444 million, reflecting ongoing investments in technology and potential market expansion post-divestiture of its Lab Products business, CareDx is positioning itself as a pivotal player in transforming patient care through groundbreaking medical technologies.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Protagonist Therapeutics, Inc. is a discovery and development company based in the United States with a market capitalization of $6.74 billion.

Operations: Protagonist Therapeutics focuses on biotechnology startups, generating $46.02 million in revenue from this segment.

Protagonist Therapeutics, despite its current unprofitability, is on a trajectory for substantial growth with projected revenue increases of 24.1% annually and anticipated profitability within three years. The firm’s robust commitment to research and development is evident from its recent FDA approvals and priority reviews for groundbreaking treatments like rusfertide for polycythemia vera. These strategic advancements not only highlight Protagonist’s innovative capabilities but also position it favorably in the biotech sector, potentially reshaping treatment standards and improving patient outcomes significantly.

Make It Happen

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com